Please use this identifier to cite or link to this item: http://repositorio.ufla.br/jspui/handle/1/43255
metadata.artigo.dc.title: Therapeutic management of patients with COVID-19: a systematic review
metadata.artigo.dc.creator: Tobaiqy, M.
Qashqary, M.
Al-Dahery, S.
Mujallad, A.
Hershan, A. A.
Kamal, M. A.
Helmi, N.
metadata.artigo.dc.subject: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
COVID-19
Hydroxychloroquine
Arbidol hydrochloride
Corticosteroids
Convalescent plasma therapy
metadata.artigo.dc.publisher: Elsevier
metadata.artigo.dc.date.issued: Sep-2020
metadata.artigo.dc.identifier.citation: TOBAIQY, M. et al. Therapeutic management of patients with COVID-19: a systematic review. Infection Prevention in Practice, [S.l.], v. 2, n. 3, Sept. 2020.
metadata.artigo.dc.description.abstract: Background Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which was declared a global pandemic by the World Health Organization on 11th March 2020. The treatment guidelines for COVID-19 vary between countries, yet there is no approved treatment to date. Aim To report any evidence of therapeutics used for the management of patients with COVID-19 in clinical practice since emergence of the virus. Methods A systematic review protocol was developed based on the PRISMA statement. Articles for review were selected from Embase, Medline and Google Scholar. Readily accessible peer-reviewed, full articles in English published from 1st December 2019 to 26th March 2020 were included. The search terms included combinations of: COVID, SARS-COV-2, glucocorticoids, convalescent plasma, antiviral and antibacterial. There were no restrictions on the types of study eligible for inclusion. Results Four hundred and forty-nine articles were identified in the literature search; of these, 41 studies were included in this review. These were clinical trials (N=3), case reports (N=7), case series (N=10), and retrospective (N=11) and prospective (N=10) observational studies. Thirty-six studies were conducted in China (88%). Corticosteroid treatment was reported most frequently (N=25), followed by lopinavir (N=21) and oseltamivir (N=16). Conclusions This is the first systematic review to date related to medication used to treat patients with COVID-19. Only 41 studies were eligible for inclusion, most of which were conducted in China. Corticosteroid treatment was reported most frequently in the literature.
metadata.artigo.dc.identifier.uri: https://www.sciencedirect.com/science/article/pii/S2590088920300251
http://repositorio.ufla.br/jspui/handle/1/43255
metadata.artigo.dc.language: en_US
Appears in Collections:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.